The state Rhineland-Palatinate awards the 2021 Innovation Prize in the category “cooperation“ to DiaSys Diagnostic Systems GmbH along with Hochschule Fresenius, University of Applied Sciences, for developing a new procalcition (PCT) test using PETIA technology.
In 2021, the prize, which is endowed with money, is awarded for the 33rd time. Due to the pandemic, the prize is virtually conferred by the Ministry of Economics, Transport, Agriculture and Viticulture together with the state working groups of the states chambers of industry, commerce and crafts on May 11, 2021.
For years, DiaSys and Hochschule Fresenius – University of Applied Sciences have closely cooperated in the areas of research, development and education. Both were honored by their appointment as core members of the IFCC PCT working group. The IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) is an association for the global advancement of clinical chemistry and laboratory medicine. The PCT Working Group has established a reference procedure for quality assurance of worldwide standardized sepsis diagnostics by procalcitonin.
The innovative reagent Procalcitonin FS, developed in cooperation with Hochschule Fresenius, is based on a further development of the PETIA technology (particle-enhanced turbidimetric immunoassay). In contrast to conventionally complex determination methods in laboratory, no special equipment is needed for handling. The PETIA method may be applied to almost all available clinical chemistry analyzers worldwide. The test guarantees precise procalcitonin results while saving both cost and time and allows early diagnosis and immediate therapeutic measures. The excellent performance characteristics of Procalcitonin FS have been confirmed in renowned medical publications since its introduction; a patent has been filed for the innovative manufacturing process of Procalcitonin FS.